z-logo
open-access-imgOpen Access
Development and Validation of a New Risk Score for Infection with Coronavirus (Ri.S.I.Co) Obtained from Treating Coronavirus Disease (COVID-19) Patients on the Field
Author(s) -
Paola Fugazzola,
Francesco Favi,
Matteo Tomasoni,
Claudia Zaghi,
Chiara Casadei,
Enrico Prosperi,
Giacomo Sermonesi,
Davide Corbella,
Federico Coccolini,
Beniamino Praticò,
Vanni Agnoletti,
Luca Ansaloni
Publication year - 2020
Publication title -
iranian red crescent medical journal
Language(s) - English
Resource type - Journals
eISSN - 2074-1812
pISSN - 2074-1804
DOI - 10.5812/ircmj.106473
Subject(s) - medicine , covid-19 , epidemiology , logistic regression , pandemic , coronavirus , prospective cohort study , radiological weapon , emergency medicine , disease , surgery , infectious disease (medical specialty)
Background: The Coronavirus Disease 2019 (COVID-19) pandemic has necessitated the alteration of the organization of entire hospitals to try to prevent them from becoming epidemiological clusters. The adopted diagnostic tools lack sensitivity or specificity. Objectives: The aim of the study was to create an easy-to-get risk score (Ri.S.I.Co., risk score for infection with the new coronavirus) developed on the field to stratify patients admitted to hospitals according to their risk of COVID-19 infection. Methods: In this prospective study, we included all patients who were consecutively admitted to the suspected COVID-19 department of the Bufalini Hospital, Cesena (Italy). All clinical, radiological, and laboratory predictors were included in the multivariate logistic regression model to create a risk model. A simplified model was internally and externally validated, and two score thresholds for stratifying the probability of COVID-19 infection were introduced. Results: From 11th March to 5th April 2020, 200 patients were consecutively admitted. A Ri.S.I.Co lower than 2 showed a higher sensitivity than SARS-Cov-2 nucleic acid detection (96.2% vs. 65.4%; P < 0.001). The presence of ground-glass pattern on the lung-CT scan had a lower sensitivity than a Ri.S.I.Co lower than 2 (88.5% vs. 96.2%; P < 0.001) and a lower specificity than a Ri.S.I.Co higher than 6 (75.0% vs. 96.9%; P < 0.001). Conclusions: We believe that the Ri.S.I.Co could allow to stratify admitted patients according to their risk, preventing hospitals from becoming the main COVID-19 carriers themselves. Furthermore, it could guide clinicians in starting therapies early in severe-onset cases with a high probability of COVID-19, before molecular SARS-CoV-2 infection is confirmed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom